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Abstract  Multidrug resistance (MDR) in a variety of 
human tumours such as renal cell carcinoma (RCC) is 
thought to be caused by expression of the MDR1 gene 
and may be reversed by applying modern chemosensifisers 
such as dexverapamil, which inhibit the MDR1 gene prod- 
uct P-glycoprotein. This preliminary report gives informa- 
tion on a clinical study complying with good clinical 
practice regulations in patients with advanced RCC. The 
final evaluation is pending. Vinblastine, if anything the 
most effective chemotherapeutic agent (5-day continuous 
regimen), was combined with oral dexverapamil (6 times 
per day) as a chemosensitiser and dexamethasone to in- 
crease dexverapamil tolerance. All patients had histologi- 
cally proven RCC, which was metastatic and progressive at 
study entry. The statistical design featured a pre-study 
regimen of two cycles of vinblastine alone followed by 
evaluation. If no response was documented, with all pa- 
tients thus serving as their own control, dexverapamil and 
dexamethasone w re added for three cycles of combination 
therapy. Having obtained institutional permission from the 
ethical review committee, we enrolled patients of whom 25 
qualified for the combined-treatment arm; 13 patients 
finished the study, 5 patients failed to complete all treat- 
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ment cycles (1 because of treatment-related toxicity, 3 for 
personal reasons, not related to treatment, 1 for tumour- 
related reasons) and 7 patients were at too early a stage for 
evaluation. Altogether, 61% of all patients tolerated a dose 
of dexverapamil of at least 2400 mg/day with peak serum 
levels reaching, in some cases, approximately 8 gM (the 
sum of dexverapamil p us nordexverapamil levels). WHO 
grade 3 and 4 toxicities were mainly myelosuppression 
(5/18). The combination of 1.4 mg m-2 day-t vinblastine 
plus dexverapamil was generally felt to be safe and well 
tolerated. One partial response and 7 stable diseases were 
noted in this heavily pretreated study population. Four- 
hourly administration of dexverapamil in combination with 
dexamethasone plus escalation to the individually tolerated 
doses have permitted increases in serum levels of dexver- 
apamil. 
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9Clinical study 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Introduction 
Renal cell carcinoma (RCC) is the third most common 
urological malignancy and accounts for approximately 3% 
of all adult tumours. The treatment of choice for non- 
disseminated disease relies on surgery. The 5-year survival 
of all stages reached 40% 40 years ago, 50% 20 years ago, 
and amounted to 60% in the recent literature. It is widely 
accepted that, in addition to refinement of operative strate- 
gies and general hospital care, the use of ultrasound in 
medicine has been of paramount importance, leading to 
earlier detection of tumours that are more frequently 
amenable to surgical resection. However, further improve- 
ment in the prognosis of RCC is most likely to depend on 
the eventual development of a systemic treatment for the 
still high number of patients presenting with metastatic 
disease. 
Therapeutic options in advanced stages, including hor- 
monal therapy or immuno- or chemotherapy, have no 
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proven efficacy, and there is an abundance of recent 
investigations using innovative forms of immunotherapy, 
gene therapy, and chemosensitisation-enhanced ch mother- 
apy. The latter strategy is the focus of this paper. 
Ever since the discovery that certain toxic drugs could 
be used to treat cancer, clinical researchers have been faced 
with the problem of drug resistance. It prevents response in 
some tumours such as RCC and develops at an alarmingly 
high frequency in some neoplasms that initially appear to 
be suitable for chemotherapy. 
Oncologists often ask why the cancers they treat with 
chemotherapy readily display or develop resistance to 
powerful anticancer drugs when their toxicity to normal 
tissues such as bone marrow and the gastrointestinal tract 
persists. In the search for answers to perplexing questions 
such as this, a cellular protein termed P-glycoprotein (Pgp) 
and encoded by the MDR1 gene (reviewed in Gottesmann 
and Pastan 1993) has been discovered. Study of drug- 
resistant cells, derived from patients and propagated in 
tissue culture, gave the surprising result that all of these 
different chemotherapeutic agents, which are easily soluble 
in cell membranes and enter cells by simple diffusion, were 
failing to accumulate in such resistant cancer cells. Further- 
more, the low cellular drug levels resulted from the pres- 
ence of an energy-dependent pump at the cell surface, 
which rapidly removed the drugs as soon as they started 
to become internalised. A molecular sump pump rescued 
these cancer cells from natural-product ytotoxic agents. 
For nearly half a century since the inception of an 
organised drug-screening programme to improve cancer 
chemotherapy, efforts have been largely compound-often- 
ted (sensitive drug screens) then disease-oriented (tumour 
panel), metastasis-oriented (orthotopic animal models) and 
recently MDR-oriented (relevant resistant drug screens). In 
fact, knowledge of the Pgp-dftven mechanism of drug 
resistance has resulted in a bold initiative in chemosensiti- 
sation-enhanced chemotherapy to intensify classical che- 
motherapy by virtue of inhibiting the underlying resistance 
factor, e.g. Pgp (reviewed in Gottesman and Pastan 1993). 
Based on an encouraging preclinical analysis using RCC 
lines (Fojo et al. 1987), primary RCC cultures (Mickisch 
et al. 1990) or transgenic mice expressing the MDR1 gene 
at levels present in RCC (Mickisch et al. 1991), a clinical 
study was initiated in patients with RCC. This is a tumour 
entity for which there are at present no reliable therapeutic 
options in advanced stages and which almost always 
expresses Pgp (Fojo et al. 1987; Kakehi et al. 1988). 
Vinblastine, if anything the most effective chemotherapeu- 
tic agent, is combined with dexverapamil, a prototype 
second-generation chemosensitiser, to test for chemomodu- 
lation. Since comprehensive animal experimentation i di- 
cated that dexamethasone markedly increased dexverapa- 
mil tolerance (Gottesman et al. 1994), this drug is also 
included in the protocol. The main study objectives for 
evaluation were toxicity and efficacy of dexverapamil n 
conjunction with vinblastine and dexamethasone in patients 
with vinblastine-resistant RCC. Additional parameters 
comprised an MDR1 expression analysis of the primary 
tumour and serum pharmacokinetics of dexverapamil, vin- 
Table 1 Dexverapamil in metastatic renal cell carcinoma (RCC). 
Patient and tmnottr characteristics 
Characteristic 
Total no. patients 18 
Age (years) 
Median 61 
Range 41 - 68 
Sex 
Female 4 
Male 14 
Prior therapies of RCC (not exclusive) 
Nephrectomy 14 
Chemotherapy 0 
Irmnunotherapy 2 
None 4 
Site of metastasis (not exclusive) 
Lung 15 
Liver 2 
Lymph node 6 
Bone 4 
Other 3 
blastine and the combination of the two drugs. Furthermore, 
an in vitro assay to determine the ability of patient serum 
containing dexverapamil to circumvent MDR of RCC lines 
was carried out at different assay times during the study. 
These results will be reported separately. 
Patients and methods 
Patients with a clinical and histological diagnosis of advanced RCC 
were studied in a two-stage (sequential) phase-II investigation comply- 
ing with good clinical practice regulations. 
Eligibility requirements 
The clinical work-up was always based on complete blood count, 
chemistry, ECG, assessment of the left ventricular ejection fraction, 
chest X-rays and computed tomography (CT) of the abdomen, which 
also served for the evaluation of the treatment results. Additional 
diagnostic procedures such as bone scans and CT of the thorax, brain 
etc. were performed if necessary. Histology relied on a surgical 
specimen from the primary tumour if available. In patients not under- 
going radical nephrectomy prior to entering the study, a needle (core) 
biopsy of the tumour mass served to prove the clinical diagnosis of 
RCC. All participants came from the regular patient population and 
were referred to us by family physicians, urologists or medical 
oncologists for further counselling and therapy of metastatic disease. 
No attempt was made to select for specific characteristics; only 
patients with a WHO performance score of 3 or more for metastasis 
to the central nervous ystem (CNS) were excluded from enrolment in 
this study. The details are compiled in Table 1. 
Informed consent was obtained from all patients before participa- 
tion in the study, and protocols and consent forms were approved for 
medical and ethical indications by the institutional protocol review 
board (MEC 124, 106-1993/12). All patients were recruited between 
May 1993 and May 1994, and all of them were treated on a general 
urology ward. 
Previous treatments such as surgery or immuno- or chemotherapy 
were permitted if a minimal waiting period of 8 weeks was observed 
before study entry and all patients exhibited at least one bidimension- 
Table 2 Dexverapamil in metastatic RCC. Tolerated dexverapamil 
daily dose (n = 18 patients) 
Daily dose (mg) Number of patients 
(cumulative) 
1500 18 (100%) 
1800 15 (83%) 
2100 15 (83%) 
2400 11 (61%) 
2700 8 (44%) 
3000 6 (33%) 
Table 3 Dexverapamil n metastatic RCC. Maximal severity in 
haematological/general toxicities (WHO grading) (n = 18 patients) 
Number of patients experiencing toxicity 
(WHO grades 0-4) 
Toxicity VBL alone VBL + dexverapamil 
0 1 2 3 4  0 1 2 3 4  
White blood cells 6 - 5 4 3 6 3 1 3 5 
Platelets 17 - 1 15 1 1 - 1 
Haemoglobin - 1 4 10 3 - 1 1 11 5 
Nausea/vomiting 13 4 1 12 5 1 
Table 4 Dexverapamil in metastatic RCC. Cumulative cardiovascular 
effects (n = 18 patients) 
Parameter VBL alone VBL + dexverapamil 
Mean heart rate (beats/min) 79.9_+6.1 70.7+6.1 
Mean blood pressure 
Systolic (mm Hg) 144.5-+ 17.9 118.8___13.4 
Diastolic (ram Hg) 84.9___ 10.4 72.0-+8.4 
Mean PQ time (ms) 157.3_+28.5 168.9_+26.3 
ally measurable metastatic lesion other than bone metastases. Local 
radiotherapy for painful tumour deposits to bone was acceptable if
completed 8 weeks prior to the first treatment cycle, and if the 
reference tumour lesion was excluded from the radiation field. No 
concomitant medication involving MDRl-related rugs or compounds 
that may affect cardiac function, such as beta blockers, were allowed 
for the whole study duration. The left ventricular ejection fraction was 
assessed at baseline, prior to combination therapy and at the end of the 
study to have a value 50% that of age-matched population controls, 
serving as the threshold for study entry/continuation. 
Treatment plan 
The treatment schedule was 2 mg/m2 vinblastine (patients 1-10; 
optional dose reduction) amended to 1.4 mg/m2 (patients l l -study 
end; optional dose intensification) as a 5-day continuous infusion. 
Dexverapamil was administered orally six times per day starting with 
250 rag/dose on days 0 and 1 with a subsequent daily dose escalation of 
6 x 50 mg up to the individual maximum tolerated ose (days 2-6). In 
addition, 2 x 20-mg/day dexamethasone was applied as a short-term 
infusion (days 0-6). The second and third cycles were continued with 
the highest olerated exverapamil dose from cycle one. Vinblastine 
and dexamethasone solutions were prepared by the hospital pharmacy 
individually for each patient in accordance with the manufacturer's 
instructions, and dexverapamil tablets were provided by Knoll AG, 
Germany. The cycle duration for each protocol was 3 weeks. All 
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Fig. 1 Dexverapamil and its first metabolite, nor-dexverapamil, serum 
levels in the patient C. E undergoing dexverapamil/vinblastine/dexa- 
methasone treatment in accordance with protocol MEC 124, 
106-1993/12. Note the combined serum levels surpass 8 gM (approx- 
imately 4000 ng/ml) 
patients were documented to be metastatic and progressive at study 
entry. 
Electrocardiograms (ECG) of all cycles of combination therapy 
were obtained every day. If a first-degree atrioventricular block 
appeared, the dose of dexverapamil was reduced until normalisation 
of the ECG. Pulse rate and blood pressure were measured every 30 min 
after intake of any dexverapamil medication, and routine haematology, 
blood chemistry and urine analysis were recorded uring all treatment 
cycles. 
Statistics 
The statistical design featured a prestudy of two cycles of vinblastine 
alone followed by tumour evaluation. If no response was documented, 
dexverapamil and dexamethasone were added for three cycles of 
combination therapy, all patients thus serving as their own control. 
The statistical evaluation followed the two-stage design by Gehan 
(1961). A sample size of 14 patients thus guaranteed that a true 
response rate of 20% would cause at least one objective response 
(~ error = 0.05). In this scheme, the trial would have been discontinued 
if no response had been observed after 14 patients, with further 
enrolment depending on the number of patients needed to estimate 
the real response rate with a required precision of 10% in terms of the 
standard error (maximum number = 25). 
Resul ts  
We report here prel iminarly on 18 patients who were 
entered into the main study protocol (combined-treatment 
arm). Thirteen o f  them are fully evaluable; 5 patients fai led 
to complete all treatment cycles but could be assessed for 
side-effects only. In this particular trial the investigators 
opted for the administration of  dexverapami l  six times per 
day and used dexamethasone to increase dexverapami l  
tolerance further. Table 2 summar ises  the accumulated 
dexverapami l  intake for all 18 evaluable patients. It is 
obvious that our administration reg imen al lows for a 
signif icant increase in daily dosage. 
We then examined how this progress in drug availabil ity 
would translate into serum levels of  dexverapamil .  F igure 1 
provides an example of  this part of  the pharmacologica l  
investigations, :clearly showing the increase in peak serum 
levels of  dexverapami l  and its metabol i te nor-dexverapa- 
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Table 5 Dexverapamil in metastatic RCC. Individual cardiovascular 
side-effects (n= 18 patients) (VBL vinblastine, AVatrioventricular) 
Parameter VBL alone VBL + dexverapamil 
Heart rate 
> 60 beats/rain 16 7 
50-59 beats/min 2 6 
40-49 beats/min 0 4 
< 40 beats/rain 0 1 
Blood pressure systolic 
> 100 mm Hg 18 5 
90-99 mm Hg 0 8 
80-89 mm Hg 0 4 
< 80 mm Hg 0 1 
AV block first degree 0 5 
AV block higher degree 0 0 
AV rhythm 0 0 
Table 6 Dexverapamil in metastatic RCC. Treatment efficacy (n = 13 
patients) (CR complete response, PR partial response, SD stable 
disease, PD progressive disease 
Response VBL alone VBL + dexverapamil 
CR 1 a - 
PR - 1 
SD 9 7 
PD 3 5 
Total 13 13 
a Later became progressive and entered the main study to reach stable 
disease 
mil, which has the same modulating activity as dexverapa- 
mil (Merry et al. 1989; H/~ugermann et al. 1990). It is 
noteworthy that the sum of the serum levels of these drugs 
surpasses 8 gM, a blood concentration previously thought 
to be difficult to reach. The true extent of this pharmaco- 
logical advantage can be gleaned from earlier measure- 
ments using racemic verapamil that never exceeded 1.5 gM 
(Ozols et al. 1987), and all of the patients remained in 
intensive-care units. 
Moreover, the question arose whether the increased 
serum levels of dexverapamil would reveal unacceptable 
side-effects, thus impeding clinical applicability of this 
approach. In Tables 3-5,  we compare haematological nd 
general toxicities, general cardiovascular effects and indi- 
vidual cardiovascular side-effects of vinblastine monother- 
apy (pre-study) and of the combined medication (main 
study). There is no doubt that we encountered some adverse 
effects, mainly myelosuppression, with our regimen that 
were, in principle, strictly associated with the chemother- 
apeutic agent vinblastine. This led to a protocol amendment 
of the vinblastine starting dose to 1.4 mg/ml instead of the 
original 2 mg/m 2. However, this toxicity was manageable, 
with some participants (n = 6) requiring hospitalisation to 
cope with the side-effects and subsequent dose reductions 
and/or delay in receiving further treatment cycles. 
Putative dexverapamil-related drawbacks were predomi- 
nantly cardiovascular, mostly mild in nature and definitely 
not life-threatening, and led to dose reductions in 5 patients 
experiencing an atrioventricular block grade I. In general, 
1.4 mg m -2 day -1 vinblastine plus dexverapamil was felt to 
be safe and reasonably well accepted. There were 5 patients 
who failed to complete all treatment cycles. In 1 case, 
myelotoxicity with severe septic complications precluded 
further participation in the study. In 3 patients treatment 
was discontinued because of progressive disease or dete- 
rioration of the performance status, and 1 patient with 
advanced RCC died of cardiopulmonary insufficiency due 
to dislocation of a caval tumour thrombus. 
Having established that very high serum levels of 
dexverapamil did not produce excessive toxicity in a 
general patient population suffering from metastatic RCC, 
we also wished to assess efficacy of this particular regimen. 
Table 6 shows 1 partial response and 7 patients with stable 
disease in this pretreated study cohort that was documented 
to be progressive at study entry and refractory to vinblastine 
monotherapy. The partial response occurred in a thoracic 
wall metastasis including recalcification of the rib lesion. 
There was a tendency of lung metastases to decrease in 3 
patients staying within the broad limit of stable disease. 
Hence, it appears that the chosen regimen and dosages 
result in marginal activity in RCC with this innovative 
treatment concept. 
Discussion 
MDR, mediated by Pgp and encoded by the MDR1 gene, is 
one of the best understood mechanisms of resistance to 
cytotoxic drugs. A growing body of evidence indicates that 
expression of MDR1 contributes to clinical resistance to 
chemotherapy. Pgp in normal tissues may be important in 
the excretion of MDR-related anticancer agents as well as 
many other compounds. 
Several clinical trials (overviewed in Sikic 1993; Ra- 
derer and Scheithauer 1993; Fan et al. 1994; Mickisch 
1994; Lehnert 1994) have attempted to modulate MDR 
by coadministration of non-cytotoxic inhibitors of Pgp, 
such as verapamil and cyclosporin A. Interpretation of 
these studies is complicated by a number of factors: (a) 
adequate concentrations of many potential modulation 
agents may not be achievable because of inherent toxic 
side-effects (e.g. hypotension and heart block with vera- 
pamil), (b) the pharmacokinetic consequences of the drug 
interactions that are produced have not been well charac- 
terised (drug levels of both modulator and cytotoxins), (c) 
the modulating drug may not be bioavailable in vivo 
because of binding to factors such as serum proteins (e.g., 
amiodarone), (d) proper controls may not be included 
(proven clinical resistance to prior therapy or a randomised 
control group without the chemosensitiser), (e) measure- 
ment of MDR1 expression by tumour cells may not be 
available, and (f) even if the tumour expresses MDR1, 
redundant mechanisms of resistance may be present in 
tumour cells. 
Nonetheless, the prognostic significance of MDR1 ex- 
pression and anecdotal observations of clinical remissions 
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with modulation of MDR have led to sustained interest in 
this area. At present, attention is being focused on clinical 
investigations using second-generation chemosensitisers, 
such as dexverapamil or others that have been selected 
for high efficacy or low toxicity in circumventing MDR. 
Clinically, there is profound scepticism about he use of 
classical chemotherapy in RCC, but since there are no 
reliable therapies for metastatic disease, innovative ap- 
proaches including chemosensitisation seem warranted. 
Recent and ongoing clinical studies in RCC have been 
conducted under phase I/II conditions. Hence, the need for 
well-controlled or randomised trials to evaluate these che- 
momodulators has become imperative. So far, three inves- 
tigations in RCC have been reported, but unfortunately, the 
initial results have not been very rewarding. There was one 
attempt to circumvent MDR in 15 patients with RCC by 
combining bolus vinblastine with infusional cyclosporin A
(Rodenburg et al. 1991). Median cyclosporin plasma levels 
reached a modest 5668 ng/ml. Thus, toxicity was described 
as minimal, and so was efficacy. 
Lately, dexniguldipine, a dihydropyridine derivative, 
was administered orally in conjunction with i.v. doxorubi- 
cin, a cytotoxic agent without activity in RCC when given 
as monotherapy. Thirty patients were recruited for this 
study (Gehling et al. 1993). Gastrointestinal toxicity was 
considerable, preventing a reasonable dose escalation. 
More recently, in a pilot study, continuous i.v. vinblas- 
tine and oral dexverapamil, the R(+) stereoisomer of 
racemic verapamil, were administered concomitantly to 
12 patients (Overmoyer et al. 1993) with continuation of 
patient accrual. Response rates have not yet been reported, 
but the study design featuring four equal daily doses of 
dexverapamil led to plasma levels associated with cardio- 
vascular side-effects so that most patients did not tolerate 
more than 1500 mg dexverapamil/day. 
On the basis of a preclinical analysis in which dexver- 
apamil was added during the long-term exposure of RCC 
lines to vinblastine (Mickisch et al. 1990) it was decided to 
apply vinblastine in a continuous infusional regimen in 
conjunction with oral dexverapamil. In addition, the dex- 
verapamil medication was distributed over six equal daily 
doses and dexverapamil tolerance was further enhanced by 
dexamethasone support. Hitherto, reports have mainly de- 
scribed dexverapamil medication broken into four equal 
daily doses without dexamethasone support (Bissett et al. 
1991; Schumacher tal. 1991; Overmoyer et al. 1993), and 
the maximum tolerated ose for dexverapamil ranged from 
1200 nag/day to 1500 mg/day. There have been two pre- 
liminary reports on four-hourly dexverapamil medication, 
either in conjunction with etoposide, prednison, oncovin 
(vincristine), cyclophosphamide, hydroxydoxorubicin 
(EPOCH) chemotherapy (Wilson et ai. 1993) or with 
taxol (Tolcher et al. 1994). Both observations document 
feasibility and reasonable tolerance for this mode of appli- 
cation. Although there is scarce experimental evidence 
suggesting that some steroid hormones may be pumped 
by Pgp (Ueda et al. 1992; Van Kalken et al. 1993), any 
significant contribution of dexamethasone to reverse MDR 
under clinical circumstances remains highly improbable. 
When evaluating this regimen, important progress was 
made in dexverapamil tolerance (Table 2) and blood 
erum levels (Fig. 1) and some activity in RCC (Table 6) 
was achieved. 
The dose and schedule of chemotherapy indicate factors 
that might strongly affect the therapeutic value of chemo- 
sensitisers. Continuous infusion of various MDR drugs 
alone has been shown to reinduce remissions in a number 
of patients with drug-refractory l mphomas in two inde- 
pendent studies, and some experimental studies proved 
long-term drug exposure to be superior in subduing drug 
resistance in Pgp-positive cancer cell lines (overviewed in 
Sikic 1993). Notably, all clinical studies where chemosen- 
sitisers have helped to amend chemotherapeutic efficacy to 
date have employed continuous infusion of cytotoxic agents 
(overviewed in Mickisch 1994). Obviously, a certain 
amount of cytotoxic drug is needed at the site of molecular 
action to kill cancer cells, and it seems conceivable that 
blocking of the Pgp function may contribute to such 
intracellular threshold concentrations being achieved more 
readily if chemosensitisers a eadded to high doses of MDR 
agents. 
To assess the activity of chemosensitisers unequivocally, 
patients need to be treated with the identical cytotoxic 
regimen, with or without he chemosensitiser. Two strate- 
gies appear feasible: one is to perform an interpatient 
comparison in prospective, randomised trials. This classic 
phase III design is mainly suitable if a standard therapy 
were to be evaluated against a new approach that had been 
active in previous phase-II investigations. Alternatively, 
intrapatient comparison, i.e. treatment of patients with 
chemotherapy alone followed by the identical chemother- 
apy supplemented with chemosensitisation, ce drug re- 
fractoriness has been established, can be used. The latter 
approach, which was also implemented in our phase II 
study, appears to offer some advantages over randomised 
comparisons: (a) clinical resistance to a particular chemo- 
therapy has been documented; (b) small patient numbers 
are required to determine whether a chemosensitiser is 
capable of overcoming drug resistance, and (c) only pa- 
tients who are known to be unresponsive to a particular 
(standard) treatment risk experiencing toxicities from an 
experimental chemosensitiser. However, the broad applica- 
tion of this step depends on the demonstration f substantial 
effectiveness in phase I - I I  trials. 
There is no doubt hat trials delineating the activity of a 
chemosensitiser should be complemented by various col- 
lateral studies to enhance the amount of information gained 
from such studies and to facilitate the proper interpretation 
of results. Issues that appear to be indispensable in this 
respect comprise (a) MDR1 expression analysis in tumour 
specimens, even though it is not known at present what 
level of MDRI expression is needed to confer clinical drug 
resistance and, thus, this cannot reasonably be used for 
discrimination or as an exclusion criterion, (b) measure- 
ment of blood serum levels of the chemosensitiser, (c)
testing of patient serum containing the chemosensitiser 
for the ability to reverse MDR in appropriate in vitro 
models, and (d) pharmacokinetics of chemotherapeutic 
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agents with and without the chemosensitiser to discern 
whether an observed clinical activity can be traced back 
to effective blocking of Pgp in cancer cells rather than 
merely being due to pharmacological interaction, leading to 
elevated concentrations or prolonged retention of the cyto- 
toxic agents. Our comprehensive protocol in RCC has 
addressed all of these points in a single study. 
There is now preliminary evidence to suggest hat the 
concept of MDR reversal can function not only in experi- 
mental sytems, but also in cancer patients. This area of 
clinical research is still in its infancy, and the lack of more 
impressive data seems little reason to discourage further 
development. Novel strategies will appear on the horizon 
that may be able to improve the clinical utility of MDR 
reversal. However, effective clinical use of chemosensiti- 
sers is a complex and difficult task, and much work must 
still be done to optimise this application further. For the 
time being, clinical MDR reversal continues to be an 
experimental pproach and should not be pursued outside 
the context of controlled trials, strictly adhering to the 
standards of clinical drug development. 
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